526
Views
23
CrossRef citations to date
0
Altmetric
Review Article

A review of current evidence for vilazodone in major depressive disorder

, , , , &
Pages 160-169 | Received 03 Oct 2012, Accepted 20 Mar 2013, Published online: 29 May 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Xiao-Fei Zhang, Lei Wu, Dong-Jun Wan, Ruo-Zhuo Liu, Zhao Dong, Min Chen & Sheng-Yuan Yu. (2015) Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder. Neuropsychiatric Disease and Treatment 11, pages 1957-1965.
Read now
Zheng-Yi Zhou, Shawn Sun, Pooja Chopra, Yichen Zhong, Todor Totev & James Signorovitch. (2015) Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics 18:11, pages 919-929.
Read now
Sheng-Min Wang, Changsu Han & Chi-Un Pae. (2015) Criticisms of drugs in early development for the treatment of depression: what can be improved?. Expert Opinion on Investigational Drugs 24:4, pages 445-453.
Read now

Articles from other publishers (20)

Bipasha BeheraUma Shankar MishraSudhir Kumar Sahoo. (2023) Development and Validation of Stability Indicating RP-HPLC Method for The Analysis of Vilazodone in Bulk form and Marketed Pharmaceutical Dosage Form. Research Journal of Pharmacy and Technology, pages 4319-4324.
Crossref
Margo Funk & Scott Beach. 2022. Torsades de Pointes. Torsades de Pointes 213 229 .
Frank Faltraco & Johannes Thome. 2020. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1 7 .
Frank Faltraco & Johannes Thome. 2022. NeuroPsychopharmacotherapy. NeuroPsychopharmacotherapy 1311 1317 .
S. Tanwar, B. Mattoo, U. Kumar, R. Dada & R. Bhatia. (2021) Does human serotonin-1A receptor polymorphism (rs6295) code for pain and associated symptoms in fibromyalgia syndrome?. Reumatismo 73:1, pages 24-31.
Crossref
Theo Battista, Gianmarco Pascarella, David Sasah Staid, Gianni Colotti, Jessica Rosati, Annarita Fiorillo, Alessia Casamassa, Angelo Luigi Vescovi, Barbara Giabbai, Marta Stefania Semrau, Sergio Fanelli, Paola Storici, Ferdinando Squitieri, Veronica Morea & Andrea Ilari. (2021) Known Drugs Identified by Structure-Based Virtual Screening Are Able to Bind Sigma-1 Receptor and Increase Growth of Huntington Disease Patient-Derived Cells. International Journal of Molecular Sciences 22:3, pages 1293.
Crossref
Glen L. Xiong, Aaron Pinkhasov, Jed P. Mangal, Heather Huang, Jeffrey Rado, Jane Gagliardi, Dustin Demoss, David Karol, Shannon Suo, Michael Lang, Marsha Stern, E. Vanessa Spearman, John Onate, Aniyizhai Annamalai, Zeina Saliba, Thomas Heinrich & Jess G. Fiedorowicz. (2020) QTc monitoring in adults with medical and psychiatric comorbidities: Expert consensus from the Association of Medicine and Psychiatry. Journal of Psychosomatic Research 135, pages 110138.
Crossref
Christina D. Martinez-Brokaw, Joshua B. Radke, Joshua G. Pierce, Alexandra Ehlers, Sean Ekins, Kelly E. Wood, Jon Maakestad, Jacqueline A. Rymer, Kenichi Tamama & Matthew D. Krasowski. (2019) Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays. BMC Clinical Pathology 19:1.
Crossref
Przemysław Zaręba, Jolanta Jaśkowska, Izabela Czekaj & Grzegorz Satała. (2019) Design, synthesis and molecular modelling of new bulky Fananserin derivatives with altered pharmacological profile as potential antidepressants. Bioorganic & Medicinal Chemistry 27:15, pages 3396-3407.
Crossref
Alan F. Schatzberg & Charles DeBattista. 2019. Schatzberg’s Manual of Psychopharmacology. Schatzberg’s Manual of Psychopharmacology.
Shannon Hughes, Jeffrey Lacasse, Reid Rogers Fuller & Jennifer Spaulding-Givens. (2017) Adverse effects and treatment satisfaction among online users of four antidepressants. Psychiatry Research 255, pages 78-86.
Crossref
Sidney H. KennedyRaymond W. LamRoger S. McIntyre, S. Valérie Tourjman, Venkat Bhat, Pierre Blier, Mehrul Hasnain, Fabrice Jollant, Anthony J. Levitt, Glenda M. MacQueen, Shane J. McInerney, Diane McIntosh, Roumen V. Milev, Daniel J. Müller, Sagar V. Parikh, Norma L. Pearson, Arun V. Ravindran & Rudolf Uher. (2016) Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder. The Canadian Journal of Psychiatry 61:9, pages 540-560.
Crossref
Z R Donaldson, B le Francois, T L Santos, L M Almli, M Boldrini, F A Champagne, V Arango, J J Mann, C A Stockmeier, H Galfalvy, P R Albert, K J Ressler & R Hen. (2016) The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription. Translational Psychiatry 6:3, pages e746-e746.
Crossref
Sheng-Min WangChangsu HanSoo-Jung LeeAshwin A. PatkarPrakash S MasandChi-Un Pae. (2016) Vilazodone for the Treatment of Depression: An Update. Chonnam Medical Journal 52:2, pages 91.
Crossref
Barry R. Rittberg. 2016. The Medical Basis of Psychiatry. The Medical Basis of Psychiatry 79 90 .
Elena Dale, Benny Bang-Andersen & Connie Sánchez. (2015) Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology 95:2, pages 81-97.
Crossref
Sheng-Min WangChangsu HanSoo-Jung LeeAshwin A PatkarPrakash S MasandChi-Un Pae. (2015) Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action. Psychiatry Investigation 12:2, pages 155.
Crossref
Changsu HanSheng-Min WangSoo-Jung LeeTae-Youn JunChi-Un Pae. (2015) Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice. Chonnam Medical Journal 51:2, pages 66.
Crossref
Connie Sanchez, Karen E. Asin & Francesc Artigas. (2015) Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 145, pages 43-57.
Crossref
Natalia M. Jasiak & Jolene R. Bostwick. (2014) Risk of QT/QTc Prolongation Among Newer Non-SSRI Antidepressants. Annals of Pharmacotherapy 48:12, pages 1620-1628.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.